Testosterone treatments: Why, when, and how?

American Family Physician

Volumn 73, Issue 9, 2006, Pages

  Margo, Katherine ^a   Winn, Robert ^b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Mazzoni Center for LGBT Health and Well being   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ESTRADIOL VALERATE; FLUOXYMESTERONE; METHYLTESTOSTERONE; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; STEROID; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE;

ACNE; ARTICLE; BODY COMPOSITION; BONE DENSITY; BONE MASS; COGNITION; DEPRESSION; GYNECOMASTIA; HEMATOCRIT; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPOGONADISM; INFLAMMATION; LIBIDO; LIVER TOXICITY; MAMMOGRAPHY; MOOD; MUSCLE STRENGTH; NAUSEA; OSTEOPOROSIS; POLYCYTHEMIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOMATOLOGY; TESTOSTERONE BLOOD LEVEL; URTICARIA; VIRILIZATION; VOICE CHANGE; WELLBEING;

ANDROGENS; DRUG ADMINISTRATION ROUTES; HUMANS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TESTOSTERONE; TREATMENT OUTCOME;

EID: 33744499161     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors [published correction appears in JAMA 1999;281:1174]. JAMA 1999;281:537-44.
2. Bhasin S, Buckwalter JG. Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl 2001;22:718-31.
3. Liverman CT, Blazer DG, eds. Testosterone and aging: clinical research directions. Washington, D.C.: National Academies Press, 2004.
4. Griffin J, Wilson J. Disorders of the testes. In: Harrison TR, Braunwald E, eds. Harrison's Principles of internal medicine. 15th ed. New York: McGraw-Hill, 2001:2143-54.
5. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589-98.
6. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, for the Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001;86:724-31.
7. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482-92.
8. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocr Pract 2002;8:440-56.
9. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981;53:58-68.
10. Davidson JM, Camargo CA, Smith ER. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab 1979;48:955-8.
11. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997;82:3793-6.
12. Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecenoate in hypogonadal men: a double blind controlled study. Clin Endocrinol (Oxf) 1981;14:49-61.
13. Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000;85:2839-53.
14. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82:2386-90.
15. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001;56:M266-72.
16. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966-72.
17. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999;84:2647-53.
18. Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997;82:1661-7.
19. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85:2670-7.
20. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, et al. Testosterone replacement therapy improves mood in hypogonadal men - a clinical research center study. J Clin Endocrinol Metab 1996;81:3578-83.
21. Dobs AS. Androgen therapy in AIDS wasting. Baillieres Clin Endocrinol Metab 1998;12:379-90.
22. Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab 2000;85:60-5.
23. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 2000;57:141-7.
24. Grinspoon S, Corcoran C, Parlman K, Costello M, Rosenthal D, Anderson E, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med 2000;133:348-55.
25. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001;86:3555-61.
26. Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci 1994;108:325-32.
27. Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind E, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology 2001;57:80-8.
28. Meikle AW, Arver S, Dobs AS, Adolfsson J, Sanders SW, Middleton RG, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 1997;49:191-6.
29. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002;282:E601-7.
30. Simon D, Charles MA, Lahlou N, Nahoul K, Oppert JM, Gouault-Heilmann M, et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care 2001;24:2149-51.
31. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001;111:261-9.
32. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause [published correction appears in Obstet Gynecol 1995;85(5 pt 1):668]. Obstet Gynecol 1995;85:529-37.
33. Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985;151:153-60.
34. Phillips E, Bauman C. Safety surveillance of esterified estrogens-methyltestosterone (Estratest and Estratest HS) replacement therapy in the United States. Clin Ther 1997;19:1070-84.
35. Gelfand MM, Wiita B. Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996. Clin Ther 1997;19:383-404.
36. Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM, et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 1999;44:1012-20.
37. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 2002;87:136-43.
38. Kaplan HS, Owett T. The female androgen deficiency syndrome. J Sex Marital Ther 1993;19:3-24.
39. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
40. The Endocrine Society. Endocrine society calls for clinical guidelines on androgens for women. Accessed online October 19, 2005, at: http://www.endo- society.org/news/press/2004/androgen-guidelines.cfm.
41. Wisniewski AB, Nguyen TT, Dobs AS. Evaluation of high-dose estrogen and high-dose estrogen plus methyltestosterone treatment on cognitive task performance in postmenopausal women. Horm Res 2002;58:150-5.
42. Bachmann GA, Leiblum SR, Sandler B, Ainsley W, Narcessian R, Shelden R, et al. Correlates of sexual desire in post-menopausal women. Maturitas 1985;7:211-6.
43. McCoy NL, Davidson JM. A longitudinal study of the effects of menopause on sexuality. Maturitas 1985;7:203-10.
44. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-36.
45. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79:1341-52.
46. Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses. J Reprod Med 1998;43:847-56.
47. Burger H, Hailes J, Nelson J, Menelaus M. Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women. Br Med J 1987;294:936-7.
48. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-8.
49. Jassal SK, Barrett-Connor E, Edelstein SL. Low bioavailable testosterone levels predict future height loss in postmenopausal women. J Bone Miner Res 1995;10:650-4.
50. Riley A, Riley E. Controlled studies on women presenting with sexual drive disorder: I. Endocrine status. J Sex Marital Ther 2000;26:269-83.
51. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 2003;10:390-8.
52. Noakes TD. Tainted glory - doping and athletic performance. N Engl J Med 2004;351:847-9.
53. Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St. Clair LS, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005;62:154-62.
54. Lawrence ME, Kirby DF. Nutrition and sports supplements: fact or fiction. J Clin Gastroenterol 2002;35:299-306.
55. Lombardo JA. Supplements and athletes. South Med J 2004;97:877-9.
56. Green GA, Catlin DH, Starcevic B. Analysis of over-the-counter dietary supplements. Clin J Sport Med 2001;11:254-9.
57. Boehringer S. Comparison of testosterone products. Pharmacist's Letter 2003;19:19-83.